Tim Smith

In all patients evaluated during a retrospective analysis, there was no statistical difference in malignancy development between patients with psoriasis and the general population, however, select subgroups of patients did appear to be at higher risk of developing cancer.

Those identified as being at higher risk included the following: males with psoriasis, those with psoriasis onset at older ages, those with psoriatic erythroderma, and those with poorly controlled psoriatic inflammation.

“We also observed that treatment with biological agents tends to reduce the risk of developing malignancy; however, no statistical significance was found,” wrote the study authors led by Tomoya Watanabe, MD, PhD, in 

. “These results suggest that periodic screening for malignancy should be recommended in patients with psoriasis having these risk factors and in those with poorly controlled psoriatic inflammation.”

The investigators recruited 360 patients with psoriasis treated at Yokohama City University Hospital in Japan, in the period between January 2015 and March 2021. Participants’ psoriasis diagnoses had to have been made by dermatologists, and the median age range ended up being about 62.

The team gathered data on the participants such as bodyweight, sex, age, height, body mass index, medical history, age at psoriasis onset, comorbidities, laboratory data, psoriasis treatment history, psoriasis type, malignancy type, age at malignancy onset, history of smoking, and treatment outcomes.

The study group was 69.4% male (250) and 30.6% female (110), and the investigators divided psoriasis types into the following 5 titles: psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, erythrodermic psoriasis, and psoriasis guttata. The participants’ malignancy rates were compared to the general population using statistics from Japan’s National Cancer Registry.

The study results identified the incidence rate of malignancy as 14.4%, or 52 out of 360 patients. The most often associated cancer was found to be colorectal cancer at 20.9%, followed then by skin cancer at 16.4%, gastric cancer at 10.4%, and then lung cancer at 10.4%.

The investigators’ age-and sex-standardized cancer incidence ratio was 1.235 (95% CI 0.952–1.601), demonstrating that while the malignancy incidence was greater for psoriasis patients with psoriasis than for the general population, there was not a statistically significant difference identified by the analysis. The researchers’ multivariate analysis demonstrated that there was a higher malignancy risk for the following groups:

Males with psoriasis (HR = 3.15; 95% CI 1.381–7.187; 

Those with psoriasis onset at older ages (HR = 1.08; 95% CI 1.058–1.111; 

Those with psoriatic erythroderma (HR = 4.44; 95% CI 1.354–14.581; 

“This study aimed to identify the risk factors for malignancy onset in patients with psoriasis in Japan,” wrote Watanabe et al. “Statistical analysis revealed that older age at psoriasis onset, male sex, and PE were risk factors for malignancy development. Furthermore, we found that treatment with biological agents might reduce the risk of malignancy initiation.”

Watanabe T, Watanabe Y, Asai C, et al. Risks of malignancies among patients with psoriasis: A cohort study of 360 patients. 

Articles

In a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.

Tim Smith | Authors

Articles

Relationship Between Plaque Psoriasis and Cancer Risk Identified